Phase 2
N=52
The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries
Cardiac Output
Bottom Line
View on ClinicalTrials.gov: NCT01841606 ↗Enrolled (actual)
52
Serious AEs
0.0%
Results posted
May 2018
Primary outcome: Primary: Change in Cardiac Output From Baseline to 20 Minutes Post-spinal — -2.05; -1.92 L/min
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Ondansetron (Drug); Normal saline (Other)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- Female
- Sponsor
- University of British Columbia
- Primary completion
- Dec 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Cardiac Output From Baseline to 20 Minutes Post-spinal |
-2.05; -1.92 | — |
Summary
Ondansetron is a medication routinely given to mothers having cesarean deliveries to help prevent and treat nausea and vomiting. The investigators are studying the hemodynamic effects of prophylactic ondansetron on parturients undergoing elective cesarean deliveries under spinal anesthesia.
Eligibility Criteria
Inclusion Criteria
- Elective CD under spinal anesthesia
- Fluency in English
Exclusion Criteria
- Contraindication to spinal anesthesiA
- Allergy to ondansetron
Data sourced from ClinicalTrials.gov (NCT01841606). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.